Antifúngicos: lo que tenemos, lo que tendremos, lo que queremos.
Antifungals: what we have, what we will have, what we want.
Palabras clave:
antimicóticos, micosis, enfermedad fúngica invasiva, resistencia antimicrobianos, nuevos antifúngicos
Resumen
Se estima que 300 millones de personas padecen alguna infección fúngica y 1,5 millones fallecen anualmente a consecuencia de ella, similar a la mortalidad por tuberculosis y tres veces más que por malaria. Cifras que pueden ser mayores pues las micosis no son de denuncia obligatoria. Con las lecciones aprendidas durante la pandemia por SARS-CoV-19, el brote 2022 por viruela del mono, la resistencia a los antibacterianos y el reconocimiento por la OMS que las micosis reciben poca atención y recursos, sumado a que los antifúngicos disponibles poseen importantes efectos adversos, escasa biodisponibilidad oral y creciente resistencia, se hace imperativo el desarrollo de nuevos antifúngicos con mejores características farmacocinéticas y farmacodinámicas, amplio espectro a costos accesibles y disponibles a nivel mundial. Es lo que queremos. Todo un reto.
Descargas
La descarga de datos todavía no está disponible.
Citas
Firacative C. Invasive fungal disease in humans: are we aware of the real impact? Mem Inst Oswaldo Cruz. 2020;115 [citado, 2022, febrero 18] disponible en: https://doi.org/10.1590/0074-02760200430.
Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi 2017;3(4):57. https://dx.doi.org/10.3390/jof3040057
Logan A, Wolfe A, Williamson JC. Antifungal Resistance and the role of new therapeutic agents. Curr Infect Dis Rep 2022;24(9):105-116. https://dx.doi.org/10.1007/s11908-022-00782-5 Organización Mundial de la Salud (OMS).
Lista de patógenos fúngicos prioritários. Octubre, 2022. [citado 2022, octubre 30] disponible en: https://www.who.int/ publications/i/item/9789240060241
Mota Fernandes C, Dasilva D, Haranahalli K, McCarthy JB, Mallamo J, Ojima I, Del Poeta M. The future of antifungal drug therapy: novel compounds and targets. Antimicrob Agents Chemother 2021;65(2):e01719-20. https://dx.doi.org/10.1128/AAC.01719-20
Perea JRA, Barberán J. Anfotericina B forma liposómica: Un perfil farmacocinético exclusivo. Una historia inacabada. Rev Esp Quimioter 2012;25(1):17-24. Disponible en: http://seq.es/seq/0214-3429/25/1/azanza.pdf
Delattin N, Cammue BP, Thevissen K. Reactive oxygen species-inducing antifungal agents and their activity against fungal bio- films. Future Med Chem 2014;6(1):77-90. https://dx.doi.org/10.4155/fmc.13.189
Darisipudi MN, Allam R, Rupanagudi KV. Polyene macrolide antifungal drugs trigger interleukin-1 b secretion by activating the NLRP3 inflammasome. PLOS One 2011;6(5):1-6. https://doi.org/10.1371/journal.pone.0019588
Forastiero A, A. C. Mesa-Arango, A. Alastruey-Izquierdo. 6 antifungal crossresistance is related to different azole target (Erg11p) modifications. Antimicrob Agents Chemother 2013;57(10):4769–4781. https://doi.org/10.1128/AAC.00477-13
Mesa-Arango AC, Trevijano-Contador N, Román E, Sánchez-Fresneda R, Casas C, Herrero E, Argüelles JC, Pla J, Cuenca-Estrella M, Zaragoza O. The production of reactive oxygen species is a universal action mechanism of amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug. Antimicrob Agents Chemother 2014;58(11):6627-6638. https://dx.doi.org/10.1128/AAC.03570-14
Rivera-Toledo E, Jiménez-Delgadillo AU, Manzano-Gayosso P. Antifúngicos poliénicos. Mecanismo de acción y aplicaciones. Rev Fac Med 2020; 63(2):7-17. https://doi. org/10.22201/fm.24484865e.2020.63.2.02.
Semis R, Nahmias M, Lev S, Frenkel M, Segal E. Evaluation of antifungal combinations of nystatin-intralipid against Aspergillus terreus using checkerboard and disk diffusion methods. J Mycol Med 2015;25(1):63-70. https://dx.doi. org/10.1016/j.mycmed.2014.12.002
Jemel S, Guillot J, Kallel K, Botterel F, Dannaoui E. Galleria mellonella for the evaluation of antifungal efficacy against medically important fungi, a narrative review. Microorganisms 2020;8(3):390. https://dx.doi.org/10.3390/microorga- nisms8030390
Mellado F, Rojas T, Cumsille C. Queratitis fúngica: revisión actual sobre diagnóstico y tratamiento. Arq Bras Of- talmol 2013;76(1):52-56. https://doi.org/10.1590/S0004-27492013000100016
Van Leeuwen MR, Golovina EA, Dijksterhuis J. The polyene antimycotics nystatin and filipin disrupt the plasma membrane, whereas natamycin inhibits endocytosis in germinating conidia of Penicillium discolor. J. Appl Microbiol 2009;106(6):1908- 1918. https://dx.doi.org/10.1111/j.1365- 2672.2009.04165.x
Meena M, Prajapati P, Ravichandran C, Sehrawat R. Natamycin: a natural preservative for food applications a review. Food Sci Biotechnol 2021;30(12):1481-1496. https://dx.doi.org/10.1007/s10068-021-00981-1
Hoenigl M, Salmanton-García J, Walsh TJ, Nucci M, Neoh CF, Jenks JD, Lackner M, Sprute R, Al-Hatmi AMS, Bassetti M, Carlesse F, Freiberger T, Koehler P, Lehrnbecher T, Kumar A, Prattes J, Richardson M, Revankar S, Slavin MA, Stemler J, Spiess B, Taj-Aldeen SJ, Warris A, Woo PCY, Young JH, Albus K, Arenz D, Arsic- Arsenijevic V, Bouchara JP, Chinniah TR, Chowdhary A, de Hoog GS, Dimopoulos G, Duarte RF, Hamal P, Meis JF, Mfinanga S, Queiroz-Telles F, Patterson TF, Rahav G, Rogers TR, Rotstein C, Wahyuningsih R, Seidel D, Cornely OA. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infect Dis 2021;21(8):e246- e257. https://dx.doi.org/10.1016/S1473-3099(20)30784-2 Erratum in: Lancet Infect Dis 2021;21(4):e81. PMID: 33606997.
Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, Hoenigl M, Jensen HE, Lagrou K, Lewis RE, Mellinghoff SC, Mer M, Pana ZD, Seidel D, Sheppard DC, Wahba R, Akova M, Alanio A, Al-Hatmi AMS, Arikan-Akdagli S, Badali H, Ben-Ami R, Bonifaz A, Bretagne S, Castagnola E, Chayakulkeeree M, Colombo AL, Corzo-León DE, Drgona L, Groll AH, Guinea J, Heussel CP, Ibrahim AS, Kanj SS, Klimko N, Lackner M, Lamoth F, Lanternier F, Lass-Floerl C, Lee DG, Lehrnbecher T, Lmimouni BE, Mares M, Maschmeyer G, Meis JF, Meletiadis J, Morrissey CO, Nucci M, Oladele R, Pagano L, Pasqualotto A, Patel A, Racil Z, Richardson M, Roilides E, Ruhnke M, Seyedmousavi S, Sidharthan N, Singh N, Sinko J, Skiada A, Slavin M, Soman R, Spellberg B, Steinbach W, Tan BH, Ullmann AJ, Vehreschild JJ, Vehreschild MJGT, Walsh TJ, White PL, Wiederhold NP, Zaoutis T, Chakrabarti A. Mucormycosis ECMM MSG Global Guideline Writing Group. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 2019;19(12):e405-e421. https://dx.doi. org/10.1016/S1473-3099(19)30312-3
Morales-López SE, Garcia-Effron G. Infections due to rare Cryptococcus species. A literature review. J Fungi 2021;7:279. https://doi.org/10.3390/jof7040279
Chen SC, Perfect J, Colombo AL, Cornely OA, Groll AH, Seidel D, Albus K, de Almedia JN Jr, Garcia-Effron G, Gilroy N, Lass-Flörl C, Ostrosky-Zeichner L, Pagano L, Papp T, Rautemaa-Richardson R, Salmanton-García J, Spec A, Steinmann J, Arikan-Akdagli S, Arenz DE, Sprute R, Duran-Graeff L, Freiberger T, Girmenia C, Harris M, Kanj SS, Roudbary M, Lortholary O, Meletiadis J, Segal E, Tuon FF, Wiederhold N, Bicanic T, Chander J, Chen YC, Hsueh PR, Ip M, Munoz P, Spriet I, Temfack E, Thompson L, Tortorano AM, Velegraki A, Govender NP. Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infect Dis 2021;21(12):e375- e386. https://dx.doi.org/10.1016/S1473-3099(21)00203-6 Erratum in: Lancet Infect Dis. 2021;21(12):e363.
Grudzinski W, Sagan J, Welc R, Luchowski R, Gruszecki WI. Molecular organization, localization and orientation of antifungal antibiotic amphotericin B in a single lipid bilayer. Sci Rep 2016;32780- 90. https://doi.org/10.1038/srep32780
Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs 2013;73(9):919-934. https://dx.doi.org/10.1007/s40265-013-0069-4
World Health Organization. Model List of Essential Medicines, 22nd List, 2021. World Health Organization; 2021. [citado 2022, noviembre 21] Disponible en: https://www.paho.org/en/documents/22st-who-model-list-essential-medicines-eml
Nocua-Báez LC, Uribe-Jerez P, Tarazona-Guaranga L, Robles R, Cortés JA. Azoles de antes y ahora: una revisión. Rev Chilena Infectol 2020;37(3):219-230. https://dx.doi.org/10.4067/s0716-10182020000 300219
Zonios DI, Bennett JE. Update on azole antifungals. Semin Respir Crit Care Med 2008;29: 198-210. https://dx.doi.org/10.1055/s-2008-1063858
Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect 2004;10 (Suppl 1):1-10. https://dx.doi. org/10.1111/j.1470-9465.2004.00841.x
Martín-Aragón S, Benedí J. Antimicóticos dermatológicos. Rev Farmacia Profesional 2004;18(7):38-49. Diponible en: https://www.elsevier.es/es-revista-farmacia-profe-sional-3-articulo-antimicoticos-dermatolo-gicos-13064579
Hamdy R, Fayed B, Hamoda AM, Rawas-Qalaji M, Haider M, Soliman SSM. Essential oil-based design and development of novel anti-Candida azoles formulation. Molecules 2020;25(6):1463. https://dx.doi. org/10.3390/molecules25061463
Pristov KE, Ghannoum MA. Resistance of Candida to azoles and echinocandins worldwide. Clin Microbiol Infect 2019;25(7):792-798. https://dx.doi.org/10.1016/j.cmi.2019.03.028.
Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, Lass-Flörl C, Lewis RE, Munoz P, Verweij PE, Warris A, Ader F, Akova M, Arendrup MC, Barnes RA, Beigelman-Aubry C, Blot S, Bouza E, Brüggemann RJM, Buchheidt D, Cadranel J, Castagnola E, Chakrabarti A, Cuenca-Estrella M, Dimopoulos G, Fortun J, Gangneux JP, Garbino J, Heinz WJ, Herbrecht R, Heussel CP, Kibbler CC, Klimko N, Kullberg BJ, Lange C, Lehrnbecher T, Löffler J, Lortholary O, Maertens J, Marchetti O, Meis JF, Pagano L, Ribaud P, Richardson M, Roilides E, Ruhnke M, Sanguinetti M, Sheppard DC, Sinkó J, Skiada A, Vehreschild MJGT, Viscoli C, Cornely OA. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 2018;24 Suppl 1:e1-e38. https://dx.doi.org/10.1016/j.cm i.2018.01.002
Brito D, Fernández J, Castillo MA, Azuero S, Hernández-Valles R, Saúl-García Y, Valero N, Villalobos R, Semprún-Hernández N, Martínez-Méndez D. Fluconazole and voriconazole susceptibility in oral colonization isolates of Candida spp. in HIV patients. Invest Clin. 2019;60(4): 275– 282. https://dx.doi.org/10.22209/IC.v- 60n4a0232.
Martínez-Méndez D, Humbría-García L, Semprún-Hernández N, Hernández-Valles R. Auricular chromoblastomycosis: a rare presentation case and review of published literature. Rev Soc Ven Microbiol 2017; 37(1):34-36. http://www.redalyc.org/articulo.oa?id=199452813008
Cortés L, Jorge A, Russi N, July A. Equino- candinas Rev Chilena Infectol 2011;28(6), 529-536. https://dx.doi.org/10.4067/S0716-10182011000700004
Brown GD, Gordon S. Immune recognition: a new receptor for beta-glucans. Nature 2001;413:36–37. https://dx.doi.org/10.1038/35092620
Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Clinical practice guideline for the management of candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62(4):e1-50. https://dx.doi. org/10.1093/cid/civ933
Zuza-Alves DL, Silva-Rocha WP, Chaves GM. An update on Candida tropicalis based on basic and clinical approaches. Front Microbiol 2017;8:1927. https://dx.doi.org/10.3389/fmicb.2017.01927.
Mikaeili A, Kavoussi H, Hashemian AH, Shabandoost Gheshtemi M, Kavoussi R. Clinico-mycological profile of tinea capitis and its comparative response to griseofulvin versus terbinafine. Curr Med Mycol 2019;5(1):15-20. https://dx.doi.org/10.18502/cmm.5.1.532.
Queiroz-Telles F, Esterre P, Perez-Blanco M, Vitale RG, Salgado CG, Bonifaz A. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med Mycol 2002;47(1):3-15 http://dx.doi. org/10.1080/13693780802538001.
Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000;46(2):171–179. https://doi.org/10.1093/jac/46.2.171.
Bhattacharya S, Sae-Tia S, Fries BC. Candidiasis and mechanisms of antifungal resistance. Antibiotics 2020;9(6):312. https://dx.doi.org/10.3390/antibiotics 9060312
Shiri T, Loyse A, Mwenge L, Chen T, Lakhi S, Chanda D, Mwaba P, Molloy SF, Heyderman RS, Kanyama C, Hosseinipour MC, Kouanfack C, Temfack E, Mfinanga S, Kivuyo S, Chan AK, Jarvis JN, Lortholary O, Jaffar S, Niessen LW, Harrison TS. Addition of flucytosine to fluconazole for the treatment of Cryptococcal meningitis in Africa: a multicountry cost-effectiveness Analysis. Clin Infect Dis 2020;70(1):26-29. https://dx.doi.org/10.1093/cid/ciz163
Limper AH, Adenis A, Le T, Harrison TS. Fungal infections in HIV/AIDS. Lancet Infect Dis 2017;17(11):e334-e343. https://dx.doi.org/10.1016/S1473-3099 (17)30303-1
Pérez-Blanco M, Hernandez R, Zeppenfeldt G, Apitz, RJ. Ajoene and 5-fluorouracil in the topical treatment of Cladophialophora carrionii chromoblastomycosis in humans: A comparative open study. Med Mycol 2003;41(6):517-520. https://dx.doi. org/10.1080/13693780310001616519
Olson JM, Troxell T. Griseofulvin. Treasure Island (FL): StatPearls Publishing; 2021. [citado 2021, Agosto 29]. Disponible en: https://www.ncbi.nlm.nih.gov/ books/NBK537323/
Estrada-Castañón R, Chávez-López G, Estrada-Chávez G, Bonifaz A. Report of 73 cases of cutaneous sporotrichosis in Mexico. An Bras Dermatol 2018;93(6):907-909. https://dx.doi.org/10.1590/abd1806-4841.20187726
Salero-Martínez D, Bonifaz A. Yoduro de potasio: su administración más allá de la esporotricosis. Dermatol Rev Mex 2019;63(2):228-231. https://dx.doi.org/10.35366/91763.
Khaitan BK, Gupta V, Asati DP, Seshadri D, Ramam M. Successful treatment outcome with itraconazole and potassium iodide in disseminated sporotrichosis. Indian J Dermatol Venereol Leprol 2018;84(1):101-104. https://dx.doi.org/10.4103/ijdvl.IJD-VL_958_16
Brilhante RSN, Silva MLQD, Pereira VS, Oliveira JS, Maciel JM, Silva INGD, Silva LG, Melo GM, Aguiar RC, Pereira-Neto W, Pires de Camargo Z, Messias A, Costa JJ, de Souza DC, Castelo-Branco M, Gadelha MF. Potassium iodide and miltefosine inhibit biofilms of Sporothrix schenckii species complex in yeast and filamentous forms. Med Mycol 2019;57:764-772. https://dx.doi.org/10.1093/mmy/myy119.
Rajan RJ, Mohanraj P, Rose W. Subcutaneous basidiobolomycosis resembling Fournier’s Gangrene. J Trop Pediatr 2017;63(3):217-220. https://dx.doi.org/10.1093/tropej/fmw075
Ryder NS, Frank I, Dupont MC. Ergosterol biosynthesis inhibition by the thiocarbamate antifungal agents tolnaftate and tolciclate. Antimicrob Agents Chemother 1986;29(5):858-860. https://dx.doi.org/10.1128/AAC.29.5.858.
Jimenez-Garcia L, Celis-Aguilar E, Díaz-Pavón G, Muñoz Estrada V, Castro-Urquizo Á, Hernández-Castillo N, Amaro-Flores E. Efficacy of topical clotrimazole vs. topical tolnaftate in the treatment of otomycosis. A randomized controlled clinical trial. Braz J Otorhinolaryngol 2020;86(3):300-307. https://dx.doi.org/10.1016/j.bjorl.2018.12.007.
Tabara K, Szewczyk AE, Bienias W, Wojciechowska A, Pastuszka M, Oszukowska M, Kaszuba A. Amorolfine vs. ciclopirox - lacquers for the treatment of onychomycosis. Postepy Dermatol Alergol 2015;32(1):40-45. https://dx.doi.org/10. 5114/pdia.2014.40968
Gupta AK, Plott T. Ciclopirox: a broad-spectrum antifungal with antibacterial and anti-inflammatory properties. Int J Dermatol 2004;43(Suppl.1):3-8. https://dx.doi. org/10.1111/j.1461-1244.2004.02380.x
Sigle HC, Schäfer-Korting M, Korting HC, Hube B, Niewerth M. In vitro investigations on the mode of action of the hydroxypyridone antimycotics rilopirox and piroctone on Candida albicans. Mycoses 2006;49(3):159-168. https://dx.doi. org/10.1111/j.1439-0507.2006.01228.x
Radadiya PS, Thornton MM, Puri RV, Yerrathota S, Dinh-Phan J, Magenheimer B, Subramaniam D, Tran PV, Zhu H, Bolisetty S, Calvet JP, Wallace DP, Sharma M. Ciclopirox olamine induces ferritinophagy and reduces cyst burden in polycystic kidney disease. JCI In- sight 2021;6(8):e141299. https://dx.doi.org/10.1172/jci.insight.141299
Yang J, Milasta S, Hu D, AlTahan AM, Interiano RB, Zhou J, Davidson J, Low J, Lin W, Bao J, Goh P, Nathwani AC, Wang R, Wang Y, Ong SS, Boyd VA, Young B, Das S, Shelat A, Wu Y, Li Z, Zheng JJ, Mishra A, Cheng Y, Qu C, Peng J, Green DR, White S, Guy RK, Chen T, Davidoff Targeting histone demethylases in MYC-driven neuroblastomas with ciclopirox. Cancer Res 2017;77(17):4626–4638.https://dx.doi.org/10.1158/0008-5472. CAN-16-0826.
Polak AM. Preclinical data and mode of action of amorolfine. Clin Exp Dermatol 1992; 17:8-12. https://dx.doi.org/10. 1159/000247588.
Davis MR, Donnelley M, Thompson GR. Ibrexafungerp: A novel oral glucan synthase inhibitor. Med Mycol 2020; 58 (5) :579-592. https://dx.doi.org/10.1093/mmy/my z083.
Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, Krause R, Lass-Flörl C, Prattes J, Spec A, Thompson GR 3rd, Wiederhold N, Jenks JD. The Antifungal Pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs 2021;81(15):1703-1729. https://dx.doi.org/10.1007/s40265-021-01611-0
Wring S, Murphy G, Atiee G, Corr C, Hyman M, Willett M, Angulo D. Clinical pharmacokinetics and drug-drug interaction potential for coadministered SCY- 078, an oral fungicidal glucan synthase inhibitor, and tacrolimus. Clin Pharmacol Drug Dev 2019; 8:60–69. https://dx.doi.org/10.1002/cpdd.588.
Lamoth F, Lewis R, Kontoyiannis D. Investigational antifungal agents for invasive mycoses: a clinical perspective. Clin Infect Dis 2022;75(3):534–544. https://doi. org/10.1093/cid/ciab1070
Gamal A, Chu S, McCormick T, Borroto-Esoda K, Angulo D, Ghannoum M. Front Cell Infect Microbiol 2021 ; 11:642358 https://doi.org/10.3389/fcimb.2021.642358
Wiederhold NP. Pharmacodynamics, mechanisms of action and resistance, and spectrum of activity of new antifungal agents. J Fungi 2022;8(8):857. https://dx.doi.org/10.3390/jof8080857
Jacobs SE, Zagaliotis P, Walsh TJ. Novel antifungal agents in clinical trials. F1000Res. 2022;10:507. https://dx.doi. org/10.12688/f1000research.28327.2
Vivjoa (Oteseconazole) Package Insert: HIGHLIGHTS OF PRESCRIBING INFORMATION. VIVJOA™ (oteseconazole). Durham, NC, USA, 2022. [citado 2022, septiembre 23] Disponible en: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215888s000lbl.pdf.
Oliver JD, Sibley GEM, Beckmann N, Dobb KS, Slater MJ, McEntee L, du Pré S, Livermore J, Bromley MJ, Wiederhold NP, Hope WW, Kennedy AJ, Law D, Birch M. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proc Natl Acad Sci USA 2016; 113(45): 12809–12814. https://dx.doi.org/10.1073/pnas.1608304113.
Olorofim Aspergillus Infection Study (OASIS) [citado 2022, septiembre 15]. Disponible en: https://clinicaltrials.gov/ ct2/show/study/NCT05101187
Cass L, Murray A, Davis A, Woodward K, Albayaty M, Ito K, Strong P, Ayrton J, Brindley C, Prosser J, Murray J, French E, Haywood P, Wallis C, Rapeport G. Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. Pharmacol Res Perspect 2021;9(1):e00690. https://dx.doi.org/10.1002/prp2.690
Opelconazole. PC945 prophylaxis or preemptive therapy against pulmonary Aspergillosis in lung transplant recipients [citada 2022, Octubre 21] Disponible en: https://clinicaltrials.gov/ct2/show/NCT05037851?term=opelconazole&draw=2&r ank=1
Shaw KJ, Ibrahim AS. Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections. J Fungi 2020;6(4):239. https://dx.doi.org/10.3390/jof6040239
Fosmanogepix Interventional efficacy and safety phase 3 double-blind, 2-arm study to investigate iv followed by oral fosmanogepix (PF-07842805) compared with iv caspofungin followed by oral fluconazole in adult participants with candidemia and/or invasive candidiasis NCT05421858. [citado 2022, septiembre 16] Disponible en: https://clinicaltrials. gov/ct2/show/NCT05421858?term=fosmanogepix&draw=2&rank=1
Skipper CP, Atukunda M, Stadelman A, Engen NW, Bangdiwala AS, Hullsiek KH, Abassi M, Rhein J, Nicol MR, Laker E, Williams DA, Mannino R, Matkovits T, Meya DB, Boulware DR. Phase I En ACT trial of the safety and tolerability of a novel oral formulation of amphotericin B. Antimicrob Agents Chemother 2020;64(10):e00838-20. https://dx.doi.org/10.1128/AAC.00838-20
Ledezma E, Apitz-Castro R. Ajoene, el principal compuesto activo derivado del ajo (Allium sativum), un nuevo agente antifúngico. Rev Iberoam Micol 2006; 23(2):75-80. https://doi.org/10.1016/S1130-1406(06)70017-1.
San Blas G, Urbina J, Marchán E, Contreras L, Sorais F, San Blas F. Inhibition of Paracoccidioides brasiliensis by ajoene is associated with blockade of phosphatidylcholine biosynthesis. Microbiology 1997; 143: 1583-1586.
Nakamoto M, Kunimura K, Suzuki JI, Kodera Y. Antimicrobial properties of hydrophobic compounds in garlic: Allicin, vinyldithiin, ajoene and diallyl polysulfides. Exp Ther Med 2020;19(2):1550-1553. https://dx.doi.org/10.3892/etm.2019.8388
Torres J, Romero H. Actividad antifúngica in vitro del ajoeno en cinco aislamientos clínicos de Histoplasma capsulatum var. capsulatum. Rev IberoamMicol 2012; 29(1):24-28. https://dx.doi.org/10.1016/j.riam.2011.04.001
Lemus-Espinoza D, Maniscalchi MT, Ledezma E, Arrieche D. Ultraestructura de Microsporum canis: un caso de Tinea Capitis tratado tópicamente con Ajoene. Saber. 2015; 27(3): 401-405. Disponible en: http://ve.scielo.org/ scielo.php?script=sci_arttext&pid= S131501622015000300005&lng=es.
Karpiński TM. Essential oils of Lamiaceae family plants as antifungals. Biomolecules 2020;10(1):103. https://dx.doi. org/10.3390/biom10010103.
Mutlu-Ingok A, Devecioglu D, Dikmetas DN, Karbancioglu-Guler F, Capanoglu E. Antibacterial, antifungal, antimyco-toxigenic, and antioxidant activities of essential oils: an updated review. Molecules 2020;25(20):4711. https://dx.doi. org/10.3390/molecules25204711
Gintjee T, Donnelley M, Thompson G. Aspiring antifungals: review of current an- tifungal pipeline developments. J Fungi 2020; 6:28. https://doi.org/10.3390/jof6010028
Ngan NTT, Flower B, Day JN. Treatment of Cryptococcal meningitis: how have we got here and where are we going? Drugs 2022;82(12):1237-1249. https://dx.doi. org/10.1007/s40265-022-017957-5
Smilnak GJ, Charalambous LT, Cutshaw D, Premji AM, Giamberardino CD, Ballard CG, Bartuska AP, Ejikeme TU, Sheng H, Verbick LZ, Hedstrom BA, Pagadala PC, McCabe AR, Perfect JR, Lad SP. Novel treatment of cryptococcal meningitis via neurapheresis therapy. J Infect Dis 2018;218(7):1147–1154. https://dx.doi.org/10.1093/infdis/jiy286
Parente-Rocha JA, Bailão AM, Amaral AC, Taborda CP, Paccez JD, Borges CL, Pereira M. antifungal resistance, metabolic routes as drug targets, and new antifungal agents: an overview about endemic dimorphic fungi. Mediators Inflamm 2017;2017:9870679. https://dx.doi.org/10.1155/2017/9870679.
Martínez-Méndez D. COVID-19, Angola y la respuesta inesperada. Rev Soc Ven Microbiol 2020; 40(2):151-154. Disponible en: https://pesquisa.bvsalud.org/global-li-terature-on-novel-coronavirus-2019-ncov/resource/pt/covidwho-1102959
World Health Organization. Segunda reunión del Comité de Emergencias del Reglamento Sanitario Internacional (2005) (RSI) sobre el brote de viruela símica en varios países. Julio 2022 [citado 2022, octubre 21]. Disponible en https://www.who.int/es/news/item/23-07-2022-second-meeting-of-the-international-health-regulations-(2005)- (ihr)-emergency-committee-regarding-the-multi-country-outbreak-of-monkeypox Ashraf N, Kubat RC,
Poplin V, Adenis AA, Denning DW, Wright L, McCotter O, Schwartz IS, Jackson BR, Chiller T, Bahr NC. Re-drawing the maps for endemic mycoses. Mycopathologia 2020;185(5):843-865. https://dx.doi.org/10.1007/s11046-020-00431-2
República Bolivariana de Venezuela. Gaceta Oficial de la República Bolivariana de Venezuela Nº 42.553. Enero de 2023 [Citado 2023, enero 22]. Disponible en: https://tugacetaoficial.com/gaceta-ofi-cial-venezuela-42553-20-01-2023.
Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi 2017;3(4):57. https://dx.doi.org/10.3390/jof3040057
Logan A, Wolfe A, Williamson JC. Antifungal Resistance and the role of new therapeutic agents. Curr Infect Dis Rep 2022;24(9):105-116. https://dx.doi.org/10.1007/s11908-022-00782-5 Organización Mundial de la Salud (OMS).
Lista de patógenos fúngicos prioritários. Octubre, 2022. [citado 2022, octubre 30] disponible en: https://www.who.int/ publications/i/item/9789240060241
Mota Fernandes C, Dasilva D, Haranahalli K, McCarthy JB, Mallamo J, Ojima I, Del Poeta M. The future of antifungal drug therapy: novel compounds and targets. Antimicrob Agents Chemother 2021;65(2):e01719-20. https://dx.doi.org/10.1128/AAC.01719-20
Perea JRA, Barberán J. Anfotericina B forma liposómica: Un perfil farmacocinético exclusivo. Una historia inacabada. Rev Esp Quimioter 2012;25(1):17-24. Disponible en: http://seq.es/seq/0214-3429/25/1/azanza.pdf
Delattin N, Cammue BP, Thevissen K. Reactive oxygen species-inducing antifungal agents and their activity against fungal bio- films. Future Med Chem 2014;6(1):77-90. https://dx.doi.org/10.4155/fmc.13.189
Darisipudi MN, Allam R, Rupanagudi KV. Polyene macrolide antifungal drugs trigger interleukin-1 b secretion by activating the NLRP3 inflammasome. PLOS One 2011;6(5):1-6. https://doi.org/10.1371/journal.pone.0019588
Forastiero A, A. C. Mesa-Arango, A. Alastruey-Izquierdo. 6 antifungal crossresistance is related to different azole target (Erg11p) modifications. Antimicrob Agents Chemother 2013;57(10):4769–4781. https://doi.org/10.1128/AAC.00477-13
Mesa-Arango AC, Trevijano-Contador N, Román E, Sánchez-Fresneda R, Casas C, Herrero E, Argüelles JC, Pla J, Cuenca-Estrella M, Zaragoza O. The production of reactive oxygen species is a universal action mechanism of amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug. Antimicrob Agents Chemother 2014;58(11):6627-6638. https://dx.doi.org/10.1128/AAC.03570-14
Rivera-Toledo E, Jiménez-Delgadillo AU, Manzano-Gayosso P. Antifúngicos poliénicos. Mecanismo de acción y aplicaciones. Rev Fac Med 2020; 63(2):7-17. https://doi. org/10.22201/fm.24484865e.2020.63.2.02.
Semis R, Nahmias M, Lev S, Frenkel M, Segal E. Evaluation of antifungal combinations of nystatin-intralipid against Aspergillus terreus using checkerboard and disk diffusion methods. J Mycol Med 2015;25(1):63-70. https://dx.doi. org/10.1016/j.mycmed.2014.12.002
Jemel S, Guillot J, Kallel K, Botterel F, Dannaoui E. Galleria mellonella for the evaluation of antifungal efficacy against medically important fungi, a narrative review. Microorganisms 2020;8(3):390. https://dx.doi.org/10.3390/microorga- nisms8030390
Mellado F, Rojas T, Cumsille C. Queratitis fúngica: revisión actual sobre diagnóstico y tratamiento. Arq Bras Of- talmol 2013;76(1):52-56. https://doi.org/10.1590/S0004-27492013000100016
Van Leeuwen MR, Golovina EA, Dijksterhuis J. The polyene antimycotics nystatin and filipin disrupt the plasma membrane, whereas natamycin inhibits endocytosis in germinating conidia of Penicillium discolor. J. Appl Microbiol 2009;106(6):1908- 1918. https://dx.doi.org/10.1111/j.1365- 2672.2009.04165.x
Meena M, Prajapati P, Ravichandran C, Sehrawat R. Natamycin: a natural preservative for food applications a review. Food Sci Biotechnol 2021;30(12):1481-1496. https://dx.doi.org/10.1007/s10068-021-00981-1
Hoenigl M, Salmanton-García J, Walsh TJ, Nucci M, Neoh CF, Jenks JD, Lackner M, Sprute R, Al-Hatmi AMS, Bassetti M, Carlesse F, Freiberger T, Koehler P, Lehrnbecher T, Kumar A, Prattes J, Richardson M, Revankar S, Slavin MA, Stemler J, Spiess B, Taj-Aldeen SJ, Warris A, Woo PCY, Young JH, Albus K, Arenz D, Arsic- Arsenijevic V, Bouchara JP, Chinniah TR, Chowdhary A, de Hoog GS, Dimopoulos G, Duarte RF, Hamal P, Meis JF, Mfinanga S, Queiroz-Telles F, Patterson TF, Rahav G, Rogers TR, Rotstein C, Wahyuningsih R, Seidel D, Cornely OA. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infect Dis 2021;21(8):e246- e257. https://dx.doi.org/10.1016/S1473-3099(20)30784-2 Erratum in: Lancet Infect Dis 2021;21(4):e81. PMID: 33606997.
Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, Hoenigl M, Jensen HE, Lagrou K, Lewis RE, Mellinghoff SC, Mer M, Pana ZD, Seidel D, Sheppard DC, Wahba R, Akova M, Alanio A, Al-Hatmi AMS, Arikan-Akdagli S, Badali H, Ben-Ami R, Bonifaz A, Bretagne S, Castagnola E, Chayakulkeeree M, Colombo AL, Corzo-León DE, Drgona L, Groll AH, Guinea J, Heussel CP, Ibrahim AS, Kanj SS, Klimko N, Lackner M, Lamoth F, Lanternier F, Lass-Floerl C, Lee DG, Lehrnbecher T, Lmimouni BE, Mares M, Maschmeyer G, Meis JF, Meletiadis J, Morrissey CO, Nucci M, Oladele R, Pagano L, Pasqualotto A, Patel A, Racil Z, Richardson M, Roilides E, Ruhnke M, Seyedmousavi S, Sidharthan N, Singh N, Sinko J, Skiada A, Slavin M, Soman R, Spellberg B, Steinbach W, Tan BH, Ullmann AJ, Vehreschild JJ, Vehreschild MJGT, Walsh TJ, White PL, Wiederhold NP, Zaoutis T, Chakrabarti A. Mucormycosis ECMM MSG Global Guideline Writing Group. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 2019;19(12):e405-e421. https://dx.doi. org/10.1016/S1473-3099(19)30312-3
Morales-López SE, Garcia-Effron G. Infections due to rare Cryptococcus species. A literature review. J Fungi 2021;7:279. https://doi.org/10.3390/jof7040279
Chen SC, Perfect J, Colombo AL, Cornely OA, Groll AH, Seidel D, Albus K, de Almedia JN Jr, Garcia-Effron G, Gilroy N, Lass-Flörl C, Ostrosky-Zeichner L, Pagano L, Papp T, Rautemaa-Richardson R, Salmanton-García J, Spec A, Steinmann J, Arikan-Akdagli S, Arenz DE, Sprute R, Duran-Graeff L, Freiberger T, Girmenia C, Harris M, Kanj SS, Roudbary M, Lortholary O, Meletiadis J, Segal E, Tuon FF, Wiederhold N, Bicanic T, Chander J, Chen YC, Hsueh PR, Ip M, Munoz P, Spriet I, Temfack E, Thompson L, Tortorano AM, Velegraki A, Govender NP. Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infect Dis 2021;21(12):e375- e386. https://dx.doi.org/10.1016/S1473-3099(21)00203-6 Erratum in: Lancet Infect Dis. 2021;21(12):e363.
Grudzinski W, Sagan J, Welc R, Luchowski R, Gruszecki WI. Molecular organization, localization and orientation of antifungal antibiotic amphotericin B in a single lipid bilayer. Sci Rep 2016;32780- 90. https://doi.org/10.1038/srep32780
Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs 2013;73(9):919-934. https://dx.doi.org/10.1007/s40265-013-0069-4
World Health Organization. Model List of Essential Medicines, 22nd List, 2021. World Health Organization; 2021. [citado 2022, noviembre 21] Disponible en: https://www.paho.org/en/documents/22st-who-model-list-essential-medicines-eml
Nocua-Báez LC, Uribe-Jerez P, Tarazona-Guaranga L, Robles R, Cortés JA. Azoles de antes y ahora: una revisión. Rev Chilena Infectol 2020;37(3):219-230. https://dx.doi.org/10.4067/s0716-10182020000 300219
Zonios DI, Bennett JE. Update on azole antifungals. Semin Respir Crit Care Med 2008;29: 198-210. https://dx.doi.org/10.1055/s-2008-1063858
Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect 2004;10 (Suppl 1):1-10. https://dx.doi. org/10.1111/j.1470-9465.2004.00841.x
Martín-Aragón S, Benedí J. Antimicóticos dermatológicos. Rev Farmacia Profesional 2004;18(7):38-49. Diponible en: https://www.elsevier.es/es-revista-farmacia-profe-sional-3-articulo-antimicoticos-dermatolo-gicos-13064579
Hamdy R, Fayed B, Hamoda AM, Rawas-Qalaji M, Haider M, Soliman SSM. Essential oil-based design and development of novel anti-Candida azoles formulation. Molecules 2020;25(6):1463. https://dx.doi. org/10.3390/molecules25061463
Pristov KE, Ghannoum MA. Resistance of Candida to azoles and echinocandins worldwide. Clin Microbiol Infect 2019;25(7):792-798. https://dx.doi.org/10.1016/j.cmi.2019.03.028.
Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, Lass-Flörl C, Lewis RE, Munoz P, Verweij PE, Warris A, Ader F, Akova M, Arendrup MC, Barnes RA, Beigelman-Aubry C, Blot S, Bouza E, Brüggemann RJM, Buchheidt D, Cadranel J, Castagnola E, Chakrabarti A, Cuenca-Estrella M, Dimopoulos G, Fortun J, Gangneux JP, Garbino J, Heinz WJ, Herbrecht R, Heussel CP, Kibbler CC, Klimko N, Kullberg BJ, Lange C, Lehrnbecher T, Löffler J, Lortholary O, Maertens J, Marchetti O, Meis JF, Pagano L, Ribaud P, Richardson M, Roilides E, Ruhnke M, Sanguinetti M, Sheppard DC, Sinkó J, Skiada A, Vehreschild MJGT, Viscoli C, Cornely OA. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 2018;24 Suppl 1:e1-e38. https://dx.doi.org/10.1016/j.cm i.2018.01.002
Brito D, Fernández J, Castillo MA, Azuero S, Hernández-Valles R, Saúl-García Y, Valero N, Villalobos R, Semprún-Hernández N, Martínez-Méndez D. Fluconazole and voriconazole susceptibility in oral colonization isolates of Candida spp. in HIV patients. Invest Clin. 2019;60(4): 275– 282. https://dx.doi.org/10.22209/IC.v- 60n4a0232.
Martínez-Méndez D, Humbría-García L, Semprún-Hernández N, Hernández-Valles R. Auricular chromoblastomycosis: a rare presentation case and review of published literature. Rev Soc Ven Microbiol 2017; 37(1):34-36. http://www.redalyc.org/articulo.oa?id=199452813008
Cortés L, Jorge A, Russi N, July A. Equino- candinas Rev Chilena Infectol 2011;28(6), 529-536. https://dx.doi.org/10.4067/S0716-10182011000700004
Brown GD, Gordon S. Immune recognition: a new receptor for beta-glucans. Nature 2001;413:36–37. https://dx.doi.org/10.1038/35092620
Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Clinical practice guideline for the management of candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62(4):e1-50. https://dx.doi. org/10.1093/cid/civ933
Zuza-Alves DL, Silva-Rocha WP, Chaves GM. An update on Candida tropicalis based on basic and clinical approaches. Front Microbiol 2017;8:1927. https://dx.doi.org/10.3389/fmicb.2017.01927.
Mikaeili A, Kavoussi H, Hashemian AH, Shabandoost Gheshtemi M, Kavoussi R. Clinico-mycological profile of tinea capitis and its comparative response to griseofulvin versus terbinafine. Curr Med Mycol 2019;5(1):15-20. https://dx.doi.org/10.18502/cmm.5.1.532.
Queiroz-Telles F, Esterre P, Perez-Blanco M, Vitale RG, Salgado CG, Bonifaz A. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med Mycol 2002;47(1):3-15 http://dx.doi. org/10.1080/13693780802538001.
Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000;46(2):171–179. https://doi.org/10.1093/jac/46.2.171.
Bhattacharya S, Sae-Tia S, Fries BC. Candidiasis and mechanisms of antifungal resistance. Antibiotics 2020;9(6):312. https://dx.doi.org/10.3390/antibiotics 9060312
Shiri T, Loyse A, Mwenge L, Chen T, Lakhi S, Chanda D, Mwaba P, Molloy SF, Heyderman RS, Kanyama C, Hosseinipour MC, Kouanfack C, Temfack E, Mfinanga S, Kivuyo S, Chan AK, Jarvis JN, Lortholary O, Jaffar S, Niessen LW, Harrison TS. Addition of flucytosine to fluconazole for the treatment of Cryptococcal meningitis in Africa: a multicountry cost-effectiveness Analysis. Clin Infect Dis 2020;70(1):26-29. https://dx.doi.org/10.1093/cid/ciz163
Limper AH, Adenis A, Le T, Harrison TS. Fungal infections in HIV/AIDS. Lancet Infect Dis 2017;17(11):e334-e343. https://dx.doi.org/10.1016/S1473-3099 (17)30303-1
Pérez-Blanco M, Hernandez R, Zeppenfeldt G, Apitz, RJ. Ajoene and 5-fluorouracil in the topical treatment of Cladophialophora carrionii chromoblastomycosis in humans: A comparative open study. Med Mycol 2003;41(6):517-520. https://dx.doi. org/10.1080/13693780310001616519
Olson JM, Troxell T. Griseofulvin. Treasure Island (FL): StatPearls Publishing; 2021. [citado 2021, Agosto 29]. Disponible en: https://www.ncbi.nlm.nih.gov/ books/NBK537323/
Estrada-Castañón R, Chávez-López G, Estrada-Chávez G, Bonifaz A. Report of 73 cases of cutaneous sporotrichosis in Mexico. An Bras Dermatol 2018;93(6):907-909. https://dx.doi.org/10.1590/abd1806-4841.20187726
Salero-Martínez D, Bonifaz A. Yoduro de potasio: su administración más allá de la esporotricosis. Dermatol Rev Mex 2019;63(2):228-231. https://dx.doi.org/10.35366/91763.
Khaitan BK, Gupta V, Asati DP, Seshadri D, Ramam M. Successful treatment outcome with itraconazole and potassium iodide in disseminated sporotrichosis. Indian J Dermatol Venereol Leprol 2018;84(1):101-104. https://dx.doi.org/10.4103/ijdvl.IJD-VL_958_16
Brilhante RSN, Silva MLQD, Pereira VS, Oliveira JS, Maciel JM, Silva INGD, Silva LG, Melo GM, Aguiar RC, Pereira-Neto W, Pires de Camargo Z, Messias A, Costa JJ, de Souza DC, Castelo-Branco M, Gadelha MF. Potassium iodide and miltefosine inhibit biofilms of Sporothrix schenckii species complex in yeast and filamentous forms. Med Mycol 2019;57:764-772. https://dx.doi.org/10.1093/mmy/myy119.
Rajan RJ, Mohanraj P, Rose W. Subcutaneous basidiobolomycosis resembling Fournier’s Gangrene. J Trop Pediatr 2017;63(3):217-220. https://dx.doi.org/10.1093/tropej/fmw075
Ryder NS, Frank I, Dupont MC. Ergosterol biosynthesis inhibition by the thiocarbamate antifungal agents tolnaftate and tolciclate. Antimicrob Agents Chemother 1986;29(5):858-860. https://dx.doi.org/10.1128/AAC.29.5.858.
Jimenez-Garcia L, Celis-Aguilar E, Díaz-Pavón G, Muñoz Estrada V, Castro-Urquizo Á, Hernández-Castillo N, Amaro-Flores E. Efficacy of topical clotrimazole vs. topical tolnaftate in the treatment of otomycosis. A randomized controlled clinical trial. Braz J Otorhinolaryngol 2020;86(3):300-307. https://dx.doi.org/10.1016/j.bjorl.2018.12.007.
Tabara K, Szewczyk AE, Bienias W, Wojciechowska A, Pastuszka M, Oszukowska M, Kaszuba A. Amorolfine vs. ciclopirox - lacquers for the treatment of onychomycosis. Postepy Dermatol Alergol 2015;32(1):40-45. https://dx.doi.org/10. 5114/pdia.2014.40968
Gupta AK, Plott T. Ciclopirox: a broad-spectrum antifungal with antibacterial and anti-inflammatory properties. Int J Dermatol 2004;43(Suppl.1):3-8. https://dx.doi. org/10.1111/j.1461-1244.2004.02380.x
Sigle HC, Schäfer-Korting M, Korting HC, Hube B, Niewerth M. In vitro investigations on the mode of action of the hydroxypyridone antimycotics rilopirox and piroctone on Candida albicans. Mycoses 2006;49(3):159-168. https://dx.doi. org/10.1111/j.1439-0507.2006.01228.x
Radadiya PS, Thornton MM, Puri RV, Yerrathota S, Dinh-Phan J, Magenheimer B, Subramaniam D, Tran PV, Zhu H, Bolisetty S, Calvet JP, Wallace DP, Sharma M. Ciclopirox olamine induces ferritinophagy and reduces cyst burden in polycystic kidney disease. JCI In- sight 2021;6(8):e141299. https://dx.doi.org/10.1172/jci.insight.141299
Yang J, Milasta S, Hu D, AlTahan AM, Interiano RB, Zhou J, Davidson J, Low J, Lin W, Bao J, Goh P, Nathwani AC, Wang R, Wang Y, Ong SS, Boyd VA, Young B, Das S, Shelat A, Wu Y, Li Z, Zheng JJ, Mishra A, Cheng Y, Qu C, Peng J, Green DR, White S, Guy RK, Chen T, Davidoff Targeting histone demethylases in MYC-driven neuroblastomas with ciclopirox. Cancer Res 2017;77(17):4626–4638.https://dx.doi.org/10.1158/0008-5472. CAN-16-0826.
Polak AM. Preclinical data and mode of action of amorolfine. Clin Exp Dermatol 1992; 17:8-12. https://dx.doi.org/10. 1159/000247588.
Davis MR, Donnelley M, Thompson GR. Ibrexafungerp: A novel oral glucan synthase inhibitor. Med Mycol 2020; 58 (5) :579-592. https://dx.doi.org/10.1093/mmy/my z083.
Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, Krause R, Lass-Flörl C, Prattes J, Spec A, Thompson GR 3rd, Wiederhold N, Jenks JD. The Antifungal Pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs 2021;81(15):1703-1729. https://dx.doi.org/10.1007/s40265-021-01611-0
Wring S, Murphy G, Atiee G, Corr C, Hyman M, Willett M, Angulo D. Clinical pharmacokinetics and drug-drug interaction potential for coadministered SCY- 078, an oral fungicidal glucan synthase inhibitor, and tacrolimus. Clin Pharmacol Drug Dev 2019; 8:60–69. https://dx.doi.org/10.1002/cpdd.588.
Lamoth F, Lewis R, Kontoyiannis D. Investigational antifungal agents for invasive mycoses: a clinical perspective. Clin Infect Dis 2022;75(3):534–544. https://doi. org/10.1093/cid/ciab1070
Gamal A, Chu S, McCormick T, Borroto-Esoda K, Angulo D, Ghannoum M. Front Cell Infect Microbiol 2021 ; 11:642358 https://doi.org/10.3389/fcimb.2021.642358
Wiederhold NP. Pharmacodynamics, mechanisms of action and resistance, and spectrum of activity of new antifungal agents. J Fungi 2022;8(8):857. https://dx.doi.org/10.3390/jof8080857
Jacobs SE, Zagaliotis P, Walsh TJ. Novel antifungal agents in clinical trials. F1000Res. 2022;10:507. https://dx.doi. org/10.12688/f1000research.28327.2
Vivjoa (Oteseconazole) Package Insert: HIGHLIGHTS OF PRESCRIBING INFORMATION. VIVJOA™ (oteseconazole). Durham, NC, USA, 2022. [citado 2022, septiembre 23] Disponible en: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215888s000lbl.pdf.
Oliver JD, Sibley GEM, Beckmann N, Dobb KS, Slater MJ, McEntee L, du Pré S, Livermore J, Bromley MJ, Wiederhold NP, Hope WW, Kennedy AJ, Law D, Birch M. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proc Natl Acad Sci USA 2016; 113(45): 12809–12814. https://dx.doi.org/10.1073/pnas.1608304113.
Olorofim Aspergillus Infection Study (OASIS) [citado 2022, septiembre 15]. Disponible en: https://clinicaltrials.gov/ ct2/show/study/NCT05101187
Cass L, Murray A, Davis A, Woodward K, Albayaty M, Ito K, Strong P, Ayrton J, Brindley C, Prosser J, Murray J, French E, Haywood P, Wallis C, Rapeport G. Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. Pharmacol Res Perspect 2021;9(1):e00690. https://dx.doi.org/10.1002/prp2.690
Opelconazole. PC945 prophylaxis or preemptive therapy against pulmonary Aspergillosis in lung transplant recipients [citada 2022, Octubre 21] Disponible en: https://clinicaltrials.gov/ct2/show/NCT05037851?term=opelconazole&draw=2&r ank=1
Shaw KJ, Ibrahim AS. Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections. J Fungi 2020;6(4):239. https://dx.doi.org/10.3390/jof6040239
Fosmanogepix Interventional efficacy and safety phase 3 double-blind, 2-arm study to investigate iv followed by oral fosmanogepix (PF-07842805) compared with iv caspofungin followed by oral fluconazole in adult participants with candidemia and/or invasive candidiasis NCT05421858. [citado 2022, septiembre 16] Disponible en: https://clinicaltrials. gov/ct2/show/NCT05421858?term=fosmanogepix&draw=2&rank=1
Skipper CP, Atukunda M, Stadelman A, Engen NW, Bangdiwala AS, Hullsiek KH, Abassi M, Rhein J, Nicol MR, Laker E, Williams DA, Mannino R, Matkovits T, Meya DB, Boulware DR. Phase I En ACT trial of the safety and tolerability of a novel oral formulation of amphotericin B. Antimicrob Agents Chemother 2020;64(10):e00838-20. https://dx.doi.org/10.1128/AAC.00838-20
Ledezma E, Apitz-Castro R. Ajoene, el principal compuesto activo derivado del ajo (Allium sativum), un nuevo agente antifúngico. Rev Iberoam Micol 2006; 23(2):75-80. https://doi.org/10.1016/S1130-1406(06)70017-1.
San Blas G, Urbina J, Marchán E, Contreras L, Sorais F, San Blas F. Inhibition of Paracoccidioides brasiliensis by ajoene is associated with blockade of phosphatidylcholine biosynthesis. Microbiology 1997; 143: 1583-1586.
Nakamoto M, Kunimura K, Suzuki JI, Kodera Y. Antimicrobial properties of hydrophobic compounds in garlic: Allicin, vinyldithiin, ajoene and diallyl polysulfides. Exp Ther Med 2020;19(2):1550-1553. https://dx.doi.org/10.3892/etm.2019.8388
Torres J, Romero H. Actividad antifúngica in vitro del ajoeno en cinco aislamientos clínicos de Histoplasma capsulatum var. capsulatum. Rev IberoamMicol 2012; 29(1):24-28. https://dx.doi.org/10.1016/j.riam.2011.04.001
Lemus-Espinoza D, Maniscalchi MT, Ledezma E, Arrieche D. Ultraestructura de Microsporum canis: un caso de Tinea Capitis tratado tópicamente con Ajoene. Saber. 2015; 27(3): 401-405. Disponible en: http://ve.scielo.org/ scielo.php?script=sci_arttext&pid= S131501622015000300005&lng=es.
Karpiński TM. Essential oils of Lamiaceae family plants as antifungals. Biomolecules 2020;10(1):103. https://dx.doi. org/10.3390/biom10010103.
Mutlu-Ingok A, Devecioglu D, Dikmetas DN, Karbancioglu-Guler F, Capanoglu E. Antibacterial, antifungal, antimyco-toxigenic, and antioxidant activities of essential oils: an updated review. Molecules 2020;25(20):4711. https://dx.doi. org/10.3390/molecules25204711
Gintjee T, Donnelley M, Thompson G. Aspiring antifungals: review of current an- tifungal pipeline developments. J Fungi 2020; 6:28. https://doi.org/10.3390/jof6010028
Ngan NTT, Flower B, Day JN. Treatment of Cryptococcal meningitis: how have we got here and where are we going? Drugs 2022;82(12):1237-1249. https://dx.doi. org/10.1007/s40265-022-017957-5
Smilnak GJ, Charalambous LT, Cutshaw D, Premji AM, Giamberardino CD, Ballard CG, Bartuska AP, Ejikeme TU, Sheng H, Verbick LZ, Hedstrom BA, Pagadala PC, McCabe AR, Perfect JR, Lad SP. Novel treatment of cryptococcal meningitis via neurapheresis therapy. J Infect Dis 2018;218(7):1147–1154. https://dx.doi.org/10.1093/infdis/jiy286
Parente-Rocha JA, Bailão AM, Amaral AC, Taborda CP, Paccez JD, Borges CL, Pereira M. antifungal resistance, metabolic routes as drug targets, and new antifungal agents: an overview about endemic dimorphic fungi. Mediators Inflamm 2017;2017:9870679. https://dx.doi.org/10.1155/2017/9870679.
Martínez-Méndez D. COVID-19, Angola y la respuesta inesperada. Rev Soc Ven Microbiol 2020; 40(2):151-154. Disponible en: https://pesquisa.bvsalud.org/global-li-terature-on-novel-coronavirus-2019-ncov/resource/pt/covidwho-1102959
World Health Organization. Segunda reunión del Comité de Emergencias del Reglamento Sanitario Internacional (2005) (RSI) sobre el brote de viruela símica en varios países. Julio 2022 [citado 2022, octubre 21]. Disponible en https://www.who.int/es/news/item/23-07-2022-second-meeting-of-the-international-health-regulations-(2005)- (ihr)-emergency-committee-regarding-the-multi-country-outbreak-of-monkeypox Ashraf N, Kubat RC,
Poplin V, Adenis AA, Denning DW, Wright L, McCotter O, Schwartz IS, Jackson BR, Chiller T, Bahr NC. Re-drawing the maps for endemic mycoses. Mycopathologia 2020;185(5):843-865. https://dx.doi.org/10.1007/s11046-020-00431-2
República Bolivariana de Venezuela. Gaceta Oficial de la República Bolivariana de Venezuela Nº 42.553. Enero de 2023 [Citado 2023, enero 22]. Disponible en: https://tugacetaoficial.com/gaceta-ofi-cial-venezuela-42553-20-01-2023.
Publicado
2023-11-21
Cómo citar
Martínez-Méndez, D., Bravo-Acosta, M., & Semprún-Hernández, N. (2023). Antifúngicos: lo que tenemos, lo que tendremos, lo que queremos.: Antifungals: what we have, what we will have, what we want. Investigación Clínica, 64(4), 539-556. https://doi.org/10.54817/IC.v64n4a11
Sección
Revisiones
